3.1.1. Effect of combination treatment of AKBA and piperine on grip strength performance in TBI rat model
The grip strength of rats was significantly reduced in the TBI control group as compared with the normal group. AKBA (25 mg/kg) and AKBA (50 mg/kg) significantly increased grip strength as compared with the TBI control group. Furthermore, AKBA (25 mg/kg) in combination with piperine (2.5 mg/kg), significantly enhanced grip strength as compared with the TBI control group, piperine per se, and AKBA treatment group and restored toward normal (Fig 2).
3.1.2. Effect of combination treatment of AKBA and piperine on rotarod test in TBI rat model
TBI control group showed a significant decrease in motor co-ordination (rotarod activity) as compared with the normal group. The rotarod activity in AKBA (25 mg/kg) and AKBA (50 mg/kg) group was significantly increased as compared with TBI control group. AKBA (25 mg/kg) in combination with piperine (2.5 mg/kg) significantly increased the rotarod activity as compared with the TBI control, piperine per se, and AKBA treatment group (Fig 3).
3.1.3. Effect of combination treatment of AKBA and piperine on open field task in TBI induced experimental rats
In the open fields task, line crossing, grooming and rearing behaviour was measured. In the TBI-induced rat group, the task activity was gradually decreased as compared with the normal group. The line crossing activity was significantly increased in AKBA (25 mg/kg) and AKBA (50 mg/kg) treated group as compared with the TBI control group. However, the combination of AKBA (25 mg/kg) with piperine (2.5 mg/kg) significantly increased the line crossing as compared with the TBI control group, piperine per se, and AKBA treatment group (Fig 4a).
After TBI, the numbers of grooming (Fig 4b) and rearing (Fig 4c) were significantly decreased in TBI-induced rat group as compared with the normal group. On the day 7, AKBA (25 mg/kg and 50 mg/kg) alone and the combination group showed significant improvement in rearing while on day 14, all treatment groups restored altered counts as compared with TBI induced rat group. In piperine treated animals, the rearing and grooming activity on day 7 as well as day 14 were significantly improved (p<0.05 and 0.01, respectively).
3.1.4. Effect of combination treatment of AKBA and piperine on narrow beam task performance (time taken to cross the beam and no. of foot slips) in TBI induced experimental rats
TBI induced rats showed an increase in the time taken to cross the beam pathway and numbers of foot slip as compared with the normal group. Treatment with AKBA (25 mg/kg) and AKBA (50 mg/kg) both significantly and dose-dependently decreased reach time and foot slips as compared to the TBI control group. Among all treatment groups, AKBA (25 mg/kg) and piperine (2.5 mg/kg) combination group at day 14 was more effective in improving narrow beam walk activity (Fig 5a and 5b).
3.1.5. Effect of combination treatment of AKBA and piperine on ELT and TSTQ in MWM TBI induced experimental rats
The TBI control group had taken more time in ELT to find out the hidden platform as compared with the normal group which clearly indicates deterioration in learning performance (p<0.001). Both doses of AKBA (25 mg/kg and 50 mg/kg) significantly improved in learning performance on day 7 whereas, at day 14, both doses of AKBA more significantly improved than day 7. However, combination with AKBA (25 mg/kg) and piperine (2.5 mg/kg) significantly decreased the escape latency and intensified the TSTQ than TBI control group, piperine per se and AKBA (25 & 50 mg/kg), which indicating memory performance retention (Fig 6a and 6b).
3.2. Biochemical parameters estimation
3.2.1. Effect of combination treatment of AKBA and piperine on brain oxidative stress parameters (LPO, nitrite, reduced GSH, catalase) in TBI induced experimental rats
The levels of LPO and nitrite were elevated significantly (p<0.001), whereas GSH and catalase levels were significantly reduced (p<0.001) in TBI induced rats as compared with the normal group. However, AKBA (25 mg/kg and 50 mg/kg) treatment group significantly alleviated (p<0.001) the level of LPO and nitrite, and the levels of GSH and catalase were significantly increased as compared with TBI induced rat group. Whereas, the combination treatment group (AKBA + piperine) significantly decreased (p<0.001) LPO and nitrite level and increased GSH and catalase level significantly (p<0.001) as compared to the TBI control group and AKBA high dose (50 mg/kg) group (Table 2).
3.3. Neuroinflammatory markers
3.3.1. Effect of combination treatment of AKBA and piperine on neuroinflammatory cytokines levels (TNF-α, IL-1β, IL-6)) in TBI induced experimental rats
The biochemical result revealed that neuroinflammatory level was changed after TBI, presented by an elevation of IL-1β (p<0.001), TNF-α (p<0.001) and IL-6 (p<0.001) as compared with the normal group. The elevated levels of IL-1β, TNF-α, and IL-6 was decreased significantly (p<0.001) after administration of AKBA (25 mg/kg and 50 mg/kg). However, combination group of AKBA (25 mg/kg) and piperine (2.5 mg/kg) significantly alleviated (p<0.001) the level of IL-1β, TNF- α, and IL-6 as compared with TBI induced group, piperine per se and 50 mg/kg of AKBA treated group (Fig 7).
3.4. Neurochemical estimation
3.4.1. Effect of combination treatment of AKBA and piperine on catecholamine levels (DA, NE, 5-HT) in TBI induced experimental rats
In the brain, dopamine is metabolized by monoamine oxidase with two intermediates, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). In comparison to the normal group, the level of catecholamines was significantly reduced (p<0.001) in the TBI control group. The treatment with AKBA 25 mg/kg and AKBA 50 mg/kg, significantly improved (p<0.001) the level of dopamine, norepinephrine, and serotonin. Also, the combination group of AKBA (25 mg/kg) and piperine (2.5 mg/kg) significantly restored (p<0.001) the level of catecholamines as compared to the TBI control group and AKBA 50 mg/kg treatment group. Further TBI-induced rats results in significant increase in the level of DOPAC and HVA. Rats treated with AKBA (25 mg/kg and 50 mg/kg) showed significantly decreased levels of DOPAC and HVA in comparison to TBI induced rats. However, the combination of AKBA (25 mg/kg) and piperine (2.5 mg/kg) significantly inhibited the increased levels of catecholamine metabolites as compared to the TBI induced rats (Table 3).
3.4.2. Effect of combination treatment of AKBA and piperine on GABA and glutamate levels in TBI induced experimental rats
TBI control group revealed that the level of GABA (cortical) was significantly decreased (p<0.001) as compared with the normal group. The treatment groups with AKBA (25 mg/kg and 50 mg/kg) prevented the GABA level alteration significantly (p<0.001) as compared with the TBI induced rats. Whereas, the combination group with AKBA (25 mg/kg) and piperine (2.5 mg/kg) more significantly improved the altered level of GABA as compared to TBI group and AKBA high dose.
In the TBI control group, there was significant elevation (p<0.001) in the level of glutamate as compared with the normal group. Treatment with AKBA (25 mg/kg and 50 mg/kg) significantly decreased (p<0.001) the altered level of glutamate as compared with the TBI induced group. Moreover, AKBA (25 mg/kg) and piperine (2.5 mg/kg) combination group significantly decreased (p<0.001) the level of glutamate as compared to the high dose of AKBA and TBI control group (Table 4).
3.5. Histopathological and immunohistological results
3.5.1. Effect of combination treatment of AKBA and piperine on neuronal loss in the cerebral cortex and hippocampal CA1 regions
Based on the results shown in hippocampal CA1 regions (figure 8A) and (cerebral cortex (CC) (figure 8B), the morphological status after TBI was examined by hematoxylin and eosin (H&E) staining. TBI control group was found to have smaller number of intact neurons in the cerebral cortex and hippocampal CA1 regions as compared to normal group rats indicating neuronal loss. 25 mg/kg and 50 mg/kg of AKBA treatments on traumatic rats significantly protected the CC and CA1 regions from neuronal loss as compared with TBI-induced rats. Moreover, the combination treatment of AKBA with piperine markedly showed protection from decline neuron numbers as compared with the TBI control group and High dose of AKBA group.
3.5.2. Effect of combination treatment of AKBA and piperine in increasing Nrf2 and NFkB positive cells in the cortical regions
As shown in figure 9, the normal rats did not have the expression of Nrf2 positive cells in the nucleus. The TBI control group enhanced Nrf2 expression in the nucleus as compared with normal rats. AKBA (25 mg/kg and 50 mg/kg) treatment significantly enhanced Nrf2 positive cell expressions (p<0.01). Moreover, the combination group with AKBA and piperine more significantly increased the Nrf2 positive cell expressions (p<0.001) which indicates the ability of AKBA to promote Nrf2 translocation from cytoplasm to nucleus and thereby initiate the biding to the downstream genes. cells (Fig 9).
Elevation of NFkB positive cell expressions was found significantly higher in the TBI control group as compared to the normal group (p<0.001). AKBA (25 mg/kg and 50 mg/kg) treatment to the TBI induced group, significantly lowered the NFkB positive cells as compared with the TBI control group (p<0.05, p<0.01, respectively). Moreover, simultaneous administration of AKBA and piperine significantly reduced the generation of NFkB positive cell expressions as compared with TBI control and AKBA high dose treatment group. (Fig 10).